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Bortezomib-induced skin eruption
Abstract
Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of
multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors.
Skin complications of bortezomib treatment are very frequent but poorly characterized. We describe the
case of a patient who developed erythematous and edematous plaques after treatment with bortezomib.
This case illustrates one of the potential reactions associated with bortezomib administration and
underlines the need to recognize and report cutaneous side effects of this new drug.
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monly reported side effects are fatigue, 
thrombocytopenia and peripheral neu-
ropathy. Although frequent, cutaneous re-
actions associated with this drug are poor-
ly documented in the literature, which 
consists mainly in phase 1 trials, phase 2 
studies and isolated case reports. Here, we 
describe an MM patient with skin toxicity 
resulting from bortezomib treatment pre-
senting as an erythematous and edema-
tous plaque eruption and review the exist-
ing literature on skin complications asso-
ciated with bortezomib administration. 
Adverse cutaneous side effects concern 
about 10–24%  [2–8] of patients and have 
been described mainly as ‘rash’  [2, 5, 6] or 
‘diffuse maculopapular rash’  [3, 4] . To 
date, only a few individual cases have been 
reported in detail, 1 case accompanied 
with a systemic hypersensitivity reaction 
 [3] , 12 patients with small-vessel vasculitis 
 [4, 7, 8] , 2 patients with Sweet syndrome  [9] 
and in 2 cases vasculitis was histologically 
demonstrated  [10, 11] .
 Case Report 
 A 59-year-old man was diagnosed as 
having IgG  MM, stage IIIA. From 1997 
to 2002, he was successively treated with 3 
cycles of vincristine, doxorubicin and 
dexamethasone chemotherapy followed 
by high-dose melphalan (200 mg m –2 ) 
treatment with autologous stem cell sup-
port, thalidomide, 7 cycles of cyclophos-
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 Abstract 
 Bortezomib (Velcade  ) is a proteasome in-
hibitor recently developed and mainly used 
for the treatment of multiple myeloma. Bor-
tezomib represents a novel class of drugs 
functioning as proteasome inhibitors. Skin 
complications of bortezomib treatment are 
very frequent but poorly characterized. We 
describe the case of a patient who devel-
oped erythematous and edematous plaques 
after treatment with bortezomib. This case 
illustrates one of the potential reactions as-
sociated with bortezomib administration 
and underlines the need to recognize and 
report cutaneous side effects of this new 
drug.  Copyright © 2008 S. Karger AG, Basel 
 Bortezomib (Velcade  ) is a proteasome 
inhibitor recently developed and mainly 
used for the treatment of multiple myelo-
ma (MM)  [1] . Bortezomib is effective 
through a number of mechanisms leading 
to apoptosis of plasma cells; its molecular 
weight is 384.237 g mol –1 . It blocks inhibi-
tory   B protein degradation, prevents nu-
clear factor    B (NF-  B) activation and in-
duces apoptosis in MM cells. Most com-
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phamide, melphalan and prednisone che-
motherapy followed by a second autolo-
gous stem cell transplantation. He relapsed 
in April 2004. Intravenous infusions of 
bortezomib treatment were started at 1.3 
mg m –2 twice weekly for 2 weeks. IgG  se-
rum paraprotein decreased from 38 to 21 g 
l –1 after 6 cycles. Grade I neuropathy ap-
peared, and as a result bortezomib treat-
ment was continued at a lower dose (1 mg 
m –2 ). On day 11 of the 8th cycle, the patient 
developed transient nonpruritic erythem-
atous and edematous plaques on the right 
arm, upper trunk, neck and face measur-
ing 1–3 cm in diameter without any associ-
ated symptoms. On day 11 of the 10th cy-
cle, he developed once again a similar rash 
in the same localization ( fig. 1 ).
 He was referred to the dermatology de-
partment where a differential diagnosis 
consisting of urticaria, Schnitzler syn-
drome, systemic lupus erythematosus, er-
ythema elevatum diutinum or plasma cell 
infiltration of the skin was discussed. 
There was an elevated erythroblast sedi-
ment rate (81 mm h –1 ); complete blood 
count, hepatic and renal function were 
normal. Antinuclear antibody, antineu-
trophil cytoplasmic antibody, antinucle-
osome antibody and complement con-
sumption were absent. Histological ex-
amination of a skin biopsy revealed a 
mononuclear cell infiltrate around vessels 
( fig. 2 ) associated with dermal edema and 
apoptotic basal keratinocytes, consistent 
with a drug-induced eruption. The skin le-
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sions disappeared spontaneously 2 weeks 
later. Bortezomib treatment was discon-
tinued thereafter as a result of the excellent 
clinical response of MM. No new lesions 
were observed during the following 
months.
 Discussion 
 We describe a case of skin eruption 
presenting as erythematous and edema-
tous plaques following bortezomib (Vel-
cade) injections.
 The recurrence of skin lesions at each 
cycle, the spontaneous healing after the in-
terruption of injections, the clinical pre-
sentation, the absence of general symp-
toms, the normal blood test results and
the histopathological examination point 
to the causative role of bortezomib. The 
other considered diagnoses (urticaria, 
Schnitzler syndrome, systemic lupus ery-
thematosus, erythema elevatum diutinum 
or plasma cell infiltration of the skin) were 
ruled out on the basis of patient history, 
clinical features and histopathological 
findings.
 Despite the high frequency of report-
ed cutaneous side effects (between 7 and 
24%)  [2–7] , the latter are poorly charac-
terized and mostly include ill-defined 
maculopapular rashes  [7–10] . One patient 
developed a maculopapular rash during 
the first cycle of treatment, which re-
lapsed during cycle 2, accompanied by 
dyspnea and arthritis, consistent with a 
systemic hypersensitivity reaction. His-
tology showed a superficial perivascular 
lymphocytic and eosinophilic infiltrate 
with prominent dermal mucin deposition 
 [3] . Four patients treated for B-cell non-
Hodgkin’s lymphoma developed small-
vessel vasculitis  [6, 7] , which resolved 
during treatment-free weekly intervals, 
without any other adverse symptom or 
antineutrophil cytoplasmic antibody  [7] . 
Six patients treated for MM developed a 
folliculitis-like rash during the second 
cycle of bortezomib with perivascular 
lymphoid infiltrates found in all cases 
 [11] . Treatment was continued and the 
skin eruption prevented with systemic 
corticoid therapy. Recently the case of a 
patient suffering from MM who devel-
oped a purpuric rash of the trunk, back, 
hands and face during cycle 2 has been 
described  [12] . Histology showed leuko-
cytoclastic vasculitis. Lesions healed fol-
lowing prednisone treatment, but reap-
peared during subsequent cycles of bor-
tezomib treatment.
 According to the available data in the 
literature, cutaneous side effects resulting 
from bortezomib treatment are not rare, 
and histopathological evaluation seems to 
be consistent with vasculitic reactions 
without systemic involvement, except for
1 case of systemic hypersensitivity reac-
tion  [3] .
 The exact pathogenesis of bortezo-
mib-induced skin eruptions remains un-
clear, but Min et al.  [13]  have proposed 
that bortezomib administration may en-
hance the release of proinflammatory cy-
tokines. In fact patients with leukoclastic 
vasculitis display a marked increase in se-
rum levels of IL-6, TNF-  and C-reactive 
protein.
 In our patient, the late occurrence of 
the eruption (4 months after the first expo-
sure to the drug) argues against an immu-
noallergic mechanism. Blood counts were 
close to normal during and before the 
eruption, thereby excluding a lymphocyte 
recovery eruption or an off-chemotherapy 
eruption. Bortezomib blocks NF-  B in the 
same way that nonsteroidal anti-inflam-
matory drugs do. Urticarial reactions due 
to nonsteroidal anti-inflammatory drugs 
can occur without involvement of an al-
lergically mediated process probably via a 
direct pharmacological effect. Therefore, 
it is tempting to propose that the bortezo-
mib-induced skin reaction in this patient 
is due to a direct pharmacological effect 
perhaps via the inhibition of the NF-  B 
rather than an immunoallergic mecha-
nism.
 In summary, we describe a case of 
drug-induced erythematous and edema-
tous plaques due to bortezomib treatment. 
It is important for the clinician to recog-
nize the potential cutaneous side effects 
associated with this treatment and to be 
aware that discontinuation of treatment is 
rarely required as the frequency of serious 
skin and systemic involvement due to 
bortezomib treatment is low.
 
 Fig. 1. Urticarial lesions on the neck of our 
patient during bortezomib treatment. 
 Fig. 2. Mononuclear cell infiltrate associ-
ated with dermal edema. 
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